Bayer: strong growth in Life Sciences
Advertisement
The Bayer Group achieved strong growth in its Life Sciences businesses in the second quarter of 2013. "At HealthCare, the launches of new pharmaceutical products are progressing considerably better than expected. And CropScience maintained its gratifying business development in a positive market environment," explained Management Board Chairman Dr. Marijn Dekkers at the presentation of the interim report for the second quarter. By contrast, sales at MaterialScience were slightly down from the prior-year period in a difficult market environment. Earnings of this subgroup were held back by lower selling prices and higher raw material costs. "We are currently maintaining our forecast for 2013, even if this appears increasingly ambitious," said Dekkers.